» Articles » PMID: 28576871

STEAP4: Its Emerging Role in Metabolism and Homeostasis of Cellular Iron and Copper

Overview
Journal J Endocrinol
Specialty Endocrinology
Date 2017 Jun 4
PMID 28576871
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Preserving energy homeostasis in the presence of stressors such as proinflammatory cytokines and nutrient overload is crucial to maintaining normal cellular function. Six transmembrane epithelial antigen of the prostate 4 (STEAP4), a metalloreductase involved in iron and copper homeostasis, is thought to play a potentially important role in the cellular response to inflammatory stress. Genome-wide association studies have linked various mutations in with the development of metabolic disorders such as obesity, metabolic syndrome and type 2 diabetes. Several studies have shown that expression of is modulated by inflammatory cytokines, hormones and other indicators of cellular stress and that STEAP4 may protect cells from damage, helping to maintain normal metabolic function. STEAP4 appears to be particularly relevant in metabolically oriented cells, such as adipocytes, hepatocytes and pancreatic islet cells. These cells struggle to maintain their function in iron or copper overloaded states, presumably due to increased oxidative stress, suggesting STEAP4's role in metal homeostasis is critical to the maintenance of cellular homeostasis in general, and in preventing the onset of metabolic disease. In this review, we explore genetic associations of with metabolic disorders, and we examine STEAP4 tissue expression, subcellular localization, regulation, structure and function as it relates to metabolic diseases. We then examine how STEAP4's role as a regulator of cellular iron and copper may relate to type 2 diabetes.

Citing Articles

Structure Bioinformatics of Six Human Integral Transmembrane Enzymes and their AlphaFold3 Predicted Water-Soluble QTY Analogs: Insights into FACE1 and STEA4 Binding Mechanisms.

Chen E, Pan E, Zhang S Pharm Res. 2025; 42(2):291-305.

PMID: 39966220 PMC: 11880043. DOI: 10.1007/s11095-025-03822-6.


Iron metabolism and the tumor microenvironment: A new perspective on cancer intervention and therapy (Review).

Bu X, Wang L Int J Mol Med. 2025; 55(3.

PMID: 39749705 PMC: 11722052. DOI: 10.3892/ijmm.2024.5480.


Metal Ion Signaling in Biomedicine.

Rodriguez R, Muller S, Colombeau L, Solier S, Sindikubwabo F, Caneque T Chem Rev. 2025; 125(2):660-744.

PMID: 39746035 PMC: 11758815. DOI: 10.1021/acs.chemrev.4c00577.


Tumor Heterogeneity of STEAP4 in Malignant Progression of Oral Squamous Cell Carcinoma.

Wu Z, Chen W, Lan Y, Fang Z, Hou Y, Yu X J Cancer. 2024; 15(20):6754-6767.

PMID: 39668818 PMC: 11632996. DOI: 10.7150/jca.101470.


An organotypic atlas of human vascular cells.

Barnett S, Cujba A, Yang L, Maceiras A, Li S, Kedlian V Nat Med. 2024; 30(12):3468-3481.

PMID: 39566559 PMC: 11645277. DOI: 10.1038/s41591-024-03376-x.


References
1.
Jabara H, Boyden S, Chou J, Ramesh N, Massaad M, Benson H . A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet. 2015; 48(1):74-8. PMC: 4696875. DOI: 10.1038/ng.3465. View

2.
Matsumoto I, Iwanami K, Inoue A, Umeda N, Tanaka Y, Sugihara M . Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012; 30(1):99-102. View

3.
Dmochowski K, Finegood D, Francombe W, Tyler B, Zinman B . Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab. 1993; 77(2):478-83. DOI: 10.1210/jcem.77.2.8345055. View

4.
Zhao N, Gao J, Enns C, Knutson M . ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J Biol Chem. 2010; 285(42):32141-50. PMC: 2952215. DOI: 10.1074/jbc.M110.143248. View

5.
Ozmen F, Ozmen M, Gelecek S, Bilgic I, Moran M, Sahin T . STEAP4 and HIF-1α gene expressions in visceral and subcutaneous adipose tissue of the morbidly obese patients. Mol Immunol. 2016; 73:53-9. DOI: 10.1016/j.molimm.2016.03.008. View